• Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., presented Phase II results showing that significantly more patients with Behcet’s disease treated with apremilast, its oral, targeted phosphodiesterase 4 inhibitor, achieved complete responses (were free from active oral ulcers) at week 12 vs. those on placebo (71 percent vs. 29 percent, p < 0.0001).